Subscribe
hynci-istockphoto-com-dollars-cash-
hynci / iStockphoto.com
13 August 2018Americas

PhRMA members invested $71.4bn in R&D in 2017

Members of the Pharmaceutical Research and Manufacturers of America (PhRMA) last year obtained the highest-ever level of investment for the industry group, recording $71.4 billion of funding in research and development (R&D).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PhRMA shames Brazil and Thailand over patent backlogs
6 November 2018   Pharmaceutical Research and Manufacturers of America has identified Brazil and Thailand as two of the worst countries for patent delays, in a submission made to a US government report.
Americas
PhRMA cuts membership, increases R&D requirements
11 May 2017   The Pharmaceutical Research and Manufacturers of America has cut 22 members based on a new set of membership criteria it introduced on Tuesday, May 9.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders